Potential Targets for Prevention and Treatment of Nonalcoholic Fatty Liver Disease in Adults: A Review

Authors

  • Jarnail Singh Braich Department of Pharmacology, Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak-124001 (IN), India.

DOI:

https://doi.org/10.9734/bpi/tipr/v8/2909F

Keywords:

Nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, hepatic fibrosis, hepatocellular carcinoma, antioxidants, n-3 PUFA, hypolipidemic drugs, insulin resistance, insulin sensitizers

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a prevalent condition that can lead to major liver diseases such as hepatic fibrosis and hepatocellular carcinoma. The most common etiology is a sedentary lifestyle and taking a high-calorie diet. Presently there is no US FDA-approved drug available to treat NAFLD, and only dietary measures, increased physical activity, exercise, antioxidants are the options. In December 2020, the Drug Controller General of India (DGCI) had approved New Drug Application (NDA) for Saroglitazar Mg to treat NAFLD in India. This review describes in detail the pathophysiology, diagnostic methods, and potential targets for NAFLD prevention and treatment.

Published

2021-07-08

How to Cite

Jarnail Singh Braich. (2021). Potential Targets for Prevention and Treatment of Nonalcoholic Fatty Liver Disease in Adults: A Review. Technological Innovation in Pharmaceutical Research Vol. 8, 49–62. https://doi.org/10.9734/bpi/tipr/v8/2909F

Issue

Technological Innovation in Pharmaceutical Research Vol. 8

Section

Chapters